A randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of VSF-173 [Vanda Pharmaceuticals] and matching placebo in healthy male and female subjects with induced excessive sleepiness

Trial Profile

A randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of VSF-173 [Vanda Pharmaceuticals] and matching placebo in healthy male and female subjects with induced excessive sleepiness

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2012

At a glance

  • Drugs VSF 173 (Primary)
  • Indications Hypersomnia
  • Focus Therapeutic Use
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 03 Jul 2012 Actual initiation date (20 Apr 2007) added as reported by European Clinical Trials Database.
    • 03 Jul 2012 Planned end date 20 Sep 2007 added as reported by European Clinical Trials Database.
    • 01 Nov 2007 Status change from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top